美国预防服务工作组修订前列腺癌筛查建议后前列腺特异性抗原检测的变化
这项回顾性队列研究利用2013年1月1日至2019年12月31日蓝十字蓝盾受益人的去标识化理赔数据,评估美国预防服务工作组(USPSTF)2017年4月草案及2018年5月最终建议发布后前列腺特异性抗原(PSA)检测率的变化。结果显示,2016年至2019年总体PSA检测率从32.5升至36.5次/100人年,相对增加12.5%(95%CI 1.1%-24.4%),且70至89岁男性检测率也上升。
要点
- 2016年至2019年总体PSA检测率从32.5升至36.5次/100人年,相对增加12.5%(95%CI 1.1%-24.4%)。
- 70至89岁男性PSA检测率从38.0升至44.2次/100人年,相对增加16.2%(95%CI 4.2%-29.0%)。
- 2017年4月后所有受益人PSA检测呈显著上升趋势,每双月期间增加0.30次/100人年(P < .001)。
核心结论
- 这项大型全国性队列研究发现,USPSTF 2017年草案声明后PSA检测率上升,逆转了早先反对对所有患者进行PSA检测的指南后的趋势。
- 在可能较少从前列腺癌筛查中获益的老年男性中也观察到检测增加。
研究设计与样本
- 本研究为回顾性队列研究,使用2013年1月1日至2019年12月31日蓝十字蓝盾40至89岁受益人的去标识化理赔数据。
- 暴露为USPSTF前列腺癌筛查建议草案(2017年4月)和最终建议(2018年5月)的发布。
- 主要结局为双月期间年龄调整的PSA检测率,比较指南变化前(2016年1月1日至12月31日)与后(2019年1月1日至12月31日)的检测率,并采用间断时间序列分析。
主要发现
- 每个双月期间合格受益人中位数为8 087 565例(范围6 407 602-8 747 308),所有纳入合格受益人中位年龄为53岁(IQR 47-59岁)。
- 2016年至2019年,平均(SD)PSA检测率从32.5(1.1)升至36.5(1.1)次/100人年,相对增加12.5%(95%CI 1.1%-24.4%)。
- 40至54岁男性PSA检测率从20.6(0.8)升至22.7(0.9)次/100人年,相对增加10.1%(95%CI -2.8%至23.7%)。
- 55至69岁男性PSA检测率从49.8(1.9)升至55.8(1.8)次/100人年,相对增加12.1%(95%CI -0.2%至25.2%)。
- 70至89岁男性PSA检测率从38.0(1.4)升至44.2(1.4)次/100人年,相对增加16.2%(95%CI 4.2%-29.0%)。
关键数值与推荐
- USPSTF 2012年指南反对对所有男性进行基于PSA的前列腺癌筛查(D级推荐)。
- USPSTF 2017年4月草案逆转2012年指南,改为对55至69岁男性支持个体化决策(C级推荐)。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: In April 2017, the US Preventive Services Task Force (USPSTF) published a draft guideline that reversed its 2012 guidance advising against prostate-specific antigen (PSA)-based screening for prostate cancer in all men (grade D), instead endorsing individual decision-making for men aged 55 to 69 years (grade C). OBJECTIVE: To evaluate changes in rates of PSA testing after revisions in the USPSTF guideline on prostate cancer screening. DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study used deidentified claims data from Blue Cross Blue Shield beneficiaries aged 40 to 89 years from January 1, 2013, through December 31, 2019. EXPOSURES: Publication of the USPSTF's draft (April 2017) and final (May 2018) recommendation on prostate cancer screening. MAIN OUTCOMES AND MEASURES: Age-adjusted rates of PSA testing in bimonthly periods were calculated, and PSA testing rates from calendar years before (January 1 to December 31, 2016) and after (January 1 to December 31, 2019) the guideline change were compared. Interrupted time series analyses were used to evaluate the association of the draft (April 2017) and published (May 2018) USPSTF guideline with rates of PSA testing. Changes in rates of PSA testing were further evaluated among beneficiaries within the age categories reflected in the guideline: 40 to 54 years, 55 to 69 years, and 70 to 89 years. RESULTS: The median number of eligible beneficiaries for each bimonthly period was 8 087 565 (range, 6 407 602-8 747 308), and the median age of all included eligible beneficiaries was 53 years (IQR, 47-59 years). Between 2016 and 2019, the mean (SD) rate of PSA testing increased from 32.5 (1.1) to 36.5 (1.1) tests per 100 person-years, a relative increase of 12.5% (95% CI, 1.1%-24.4%). During the same period, mean (SD) rates of PSA testing increased from 20.6 (0.8) to 22.7 (0.9) tests per 100 person-years among men aged 40 to 54 years (relative increase, 10.1%; 95% CI, -2.8% to 23.7%), from 49.8 (1.9) to 55.8 (1.8) tests per 100 person-years among men aged 55 to 69 years (relative increase, 12.1%; 95% CI, -0.2% to 25.2%), and from 38.0 (1.4) to 44.2 (1.4) tests per 100 person-years among men aged 70 to 89 years (relative increase, 16.2%; 95% CI, 4.2%-29.0%). Interrupted time series analysis revealed a significantly increasing trend of PSA testing after April 2017 among all beneficiaries (0.30 tests per 100 person-years for each bimonthly period; P < .001). CONCLUSIONS AND RELEVANCE: This large national cohort study found that rates of PSA testing increased after the USPSTF's draft statement in 2017, reversing trends seen after earlier guidance against PSA testing for all patients. Increased testing was also observed among older men, who may be less likely to benefit from prostate cancer screening.
引用
- Leapman MS, Wang R, Park H, et al. Changes in Prostate-Specific Antigen Testing Relative to the Revised US Preventive Services Task Force Recommendation on Prostate Cancer Screening. JAMA Oncol. 2022. PMID: 34762100. doi:10.1001/jamaoncol.2021.5143
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。